BASIS OF PRESENTATION AND SIGNIFICANT ACCCOUNTING POLICIES - Additional Information (Details) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023 USD ($) clinicalTrial	Jun. 30, 2023 USD ($) clinicalTrial	Dec. 31, 2022 USD ($)	Jan. 01, 2022 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Research and development		$ 7,500
Cost of goods sold, potential increase from included costs	$ 100	$ 100
Number of Phase1/2 clinical trials in process | clinicalTrial		1
Number of Phase 3 clinical trials in process | clinicalTrial	3	3
Intangible asset impairment	$ 3,700	$ 3,700
Reduction in additional paid-in capital	(1,306,517)	(1,306,517)	$ (1,059,975)
Reduction in accumulated deficit	$ (1,186,184)	$ (1,186,184)	$ (1,014,223)
Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Convertible notes payable				$ 44,700
Reduction in additional paid-in capital				74,900
Reduction in accumulated deficit				$ 30,200